Wednesday, February 19, 2020 9:15:10 PM
Lurbinectedin receives Orphan Drug designation from the TGA for Small-Cell Lung Cancer in Australia
Madrid, February 19th, 2020. PharmaMar (MSE:PHM) has announced that the Australian Therapeutic Goods Administration (TGA), has designated Orphan Drug status to lurbinectedin for the treatment of Small-Cell Lung Cancer (SCLC).
On May 17th, 2017, PharmaMar and Specialised Therapeutics Asia Pte, Ltd (STA) announced an agreement to market lurbinectedin in Australia, New Zealand and in 12 Asian countries (Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Papua New Guinea, Philippines, Singapore, Timor-Leste, Thailand and Vietnam).
SCLC is a very aggressive cancer that is usually diagnosed with advanced, often metastatic disease, thus limiting the role of traditional approaches and usually posing a worse prognosis when compared to other lung cancers[1]. In Australia and New Zealand, approximately 15% of lung cancers are Small Cell[2]. More than 15,000 new cases of lung cancer are recorded in the above countries every year[3].
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM